Real-World Comparative Effectiveness of Tofacitinib and Tumor Necrosis Factor Inhibitors as Monotherapy and Combination Therapy for Treatment of Rheumatoid Arthritis

ConclusionsIn clinical practice, TNFi efficacy is improved with concomitant MTX in the second and third line. In the third/fourth line, patients are likely to achieve similar efficacy with tofacitinib monotherapy, or TNFi or tofacitinib in combination with MTX.FundingPfizer Inc

http://link.springer.com/10.1007/s40744-019-00177-4

Source: Rheumatology and Therapy - November 8, 2019 Category: Rheumatology Source Type: research